Skip to main content
Premium Trial:

Request an Annual Quote

Sagres Discovery Raises $20M in Venture Capital

NEW YORK, Oct. 3 – Oncogenomics company Sagres Discovery said Wednesday it had raised $20 million in a second round of private financing.

Sagres of Davis, Calif., said it would use the fresh influx of funds to develop its collection of genes associated with cancer and to form deals with partners to develop antibody and small molecule treatments. The company is also planning to build its senior management and pre-clinical research teams.

"The biotechnology industry has entered the post-genomics era and Sagres is making the most of a unique opportunity to identify cancer-causing genes and convert them into novel drug targets to create innovative and targeted therapeutics," David Ferrick, CEO of Sagres Discovery, said in a statement. 

Forward Ventures led the financing round. Novartis BioVentures Fund, Burrill Biotechnology Capital Fund, Axiom Venture Partners, Blue Dot Capital, Walden VC, JAFCO, and China Development Industrial Bank also participated in the financing round. 

Earlier this week Sagres said it signed a multi-year subscription agreement with Celera for its Celera Discovery System product suite.  

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.